Rocket Lab's defense contracts and backlog position it to benefit from national-security spending. Its $2.36B backlog includes over 100 booked launches, with an $816M SDA satellite deal and a $266M Space Force HASTE deal for hypersonic testing. Despite the Neutron delay, its $36B valuation offers one of the space sector's best risk-reward setups: exposure to the same defense and space-infrastructure trend as SpaceX at a fraction of its valuation. Rocket Lab is headed above $100. x.com 

Rocket Lab's growing Space Systems business positions it to provide more than launches for the space economy. It generated $189.5M in Q2, 81% of revenue; if its pending Iridium acquisition closes, it would gain a global satellite communications network. At about $51, this is one of the most compelling long-term opportunities in the space sector over 3-5 years, provided it keeps executing. Neutron's launch has slipped to 2027, and execution risks remain. x.com  x.com  x.com 

Repeated Neutron delays undermine the premium on Rocket Lab stock when execution keeps slipping. The company does not live or die by Neutron, but 50x sales was unjustified; even at 26x 2027 sales, a legitimate price suggests another 50% decline. x.com  x.com 

Rocket Lab is underestimated as a launch company when it is building a broader space infrastructure business, where satellites, components, spacecraft systems and national-security demand could matter as much as launches. It just signed its largest commercial Electron deal by mission count, 20 launches for Synspective from 2028 to 2031, per Wall St Engine, pushing its launch backlog above 100 missions. x.com 

Rocket Lab keeps executing: the US Space Force awarded it a $397M contract to build multiple advanced Flatellite spacecraft for the SB-AMTI program, which detects and tracks airborne threats in real time, and to launch them on Neutron. x.com 

Rocket Lab's delayed Neutron first flight pushes out a key part of its planned launch capacity. Flight one has moved to 2027, at least 1.5 years later than the previously indicated timing; the lack of clearer guidance is frustrating. The stock could fall 50% if it breaks key support, though that downside is conditional. x.com  x.com  x.com 

Investors rotating into cheaper stocks with more upside should ultimately benefit Rocket Lab and AST SpaceMobile. Both have already suffered major drawdowns. x.com 

Rocket Lab is set up for a breakout as its technicals and fundamentals align. A W-bottom is forming, with price bouncing off $64.6 support. Q2 revenue hit a record $234 million, up 62% year over year, and backlog rose 137% to an all-time high of $2.36 billion. It won a $397 million Space Force SB-AMTI contract to build and launch Flatellites on Neutron and joined the $981 million NITE-STAR contract ceiling, showing it is a vertically integrated space company, not just a launch provider. x.com 

Rocket Lab shares look set to grind as Neutron's first flight slips, even though the core business is at its strongest. Q2 revenue hit a record $234.1M, up 62%, and backlog rose 137% to $2.356B. But the Q3 guide cuts GAAP gross margin to 29-31% from 36.1%, below the ~37.6% expected, with adjusted EBITDA losses widening to $17-23M on low-margin satellite programs, Mynaric integration and Neutron spending. A Q1 2027 Neutron debut is now the base case, which will disappoint high expectations. x.com 

Rocket Lab's biggest-ever launch contract locks in multi-year defense work and a new US launch site, a solid backlog signal. The $266 million US Space Force award covers 12 guaranteed suborbital test launches for missile-defense work, with options for six more, flying mostly from a new Rocket Lab site in Alaska starting no earlier than the end of 2026. x.com